<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="0ad2efd3-3c6e-4cb8-8d82-3aa7ae84a81a"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>These highlights do not include all the information needed to use ADENOSINE INJECTIONÂ safely and effectively.  See full prescribing information for ADENOSINE INJECTION.<br/>
      <br/>ADENOSINE injection, for intravenous use<br/>Initial U.S. Approval: 1995<br/>
   </title>
   <effectiveTime value="20250414"/>
   <setId root="b6851256-6cef-4f23-8129-19bb64380cd5"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="080548348" root="1.3.6.1.4.1.519.1"/>
            <name>Meitheal Pharmaceuticals Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="92d89e35-e8d0-4e41-85d8-e743adf05669"/>
               <code code="48780-1" displayName="SPL LISTING DATA ELEMENTS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20241030"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="71288-207" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Adenosine</name>
                        <formCode code="C42945" displayName="INJECTION, SOLUTION" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Adenosine</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="3"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="K72T3FS567" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ADENOSINE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="K72T3FS567" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ADENOSINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="20"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43216" displayName="VIAL, SINGLE-USE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="10" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="71288-207-21" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250430"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA077425" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250430"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" displayName="INTRAVENOUS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="71288-208" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Adenosine</name>
                        <formCode code="C42945" displayName="INJECTION, SOLUTION" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Adenosine</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="3"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="K72T3FS567" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ADENOSINE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="K72T3FS567" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ADENOSINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43216" displayName="VIAL, SINGLE-USE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="71288-208-30" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250430"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA077425" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250430"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" displayName="INTRAVENOUS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="LINK_c1376895-e3fa-4e42-abbb-02a2bf63413d">
               <id root="0d138fb9-f09d-4b52-84ae-814f4cae681f"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Adenosine injection is indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately.</paragraph>
               </text>
               <effectiveTime value="20241030"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Adenosine injection, a pharmacologic stress agent, is indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately (<linkHtml href="#LINK_c1376895-e3fa-4e42-abbb-02a2bf63413d">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_dc7715a2-9618-4979-87c8-a63634ef600e">
               <id root="33ee3cda-7121-4011-8b82-04bcf7b7d14f"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>The recommended adenosine injection dose is 0.14 mg/kg/min infused over six minutes (total dose of 0.84 mg/kg) (Table 1).</paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>Administer adenosine injection only as a continuous peripheral intravenous infusion</item>
                     <item>Inject Thallium-201 at the midpoint of the adenosine injection infusion (i.e., after the first three minutes of adenosine injection)</item>
                     <item>Thallium-201 is physically compatible with adenosine injection and may be injected directly into the adenosine injection infusion set</item>
                     <item>Inject Thallium-201 as close to the venous access as possible to prevent an inadvertent increase in the dose of adenosine injection (the contents of the intravenous tubing) being administered</item>
                  </list>
                  <paragraph>Visually inspect adenosine injection for particulate matter and discoloration prior to administration. Do not administer adenosine injection if it contains particulate matter or is discolored.</paragraph>
                  <paragraph>There are no data on the safety or efficacy of alternative adenosine injection infusion protocols. The safety and efficacy of adenosine injection administered by the intracoronary route have not been established.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Table 1 Dosage Chart for Adenosine Injection</content>
                  </paragraph>
                  <table>
                     <colgroup>
                        <col width="17%"/>
                        <col width="25%"/>
                     </colgroup>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                              <paragraph>
                                 <content styleCode="bold">Patient Weight<br/>
                                    <content styleCode="italics">(kilograms)</content>
                                 </content>
                              </paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                              <paragraph>
                                 <content styleCode="bold">Infusion Rate<br/>
                                    <content styleCode="italics">(mL per minute over 6 <br/>minutes for total dose of</content>
                                 </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">0.84 mg/kg)</content>
                                 </content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>45</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                              <paragraph>2.1</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>50</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                              <paragraph>2.3</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>55</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                              <paragraph>2.6</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>60</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                              <paragraph>2.8</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>65</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                              <paragraph>3</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>70</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                              <paragraph>3.3</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>75</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                              <paragraph>3.5</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>80</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                              <paragraph>3.8</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>85</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                              <paragraph>4</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                              <paragraph>90</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                              <paragraph>4.2</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>The nomogram displayed in Table 1 was derived from the following general formula:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L53d3399a-3332-4f0d-8223-e67e423cef41"/>
                  </paragraph>
               </text>
               <effectiveTime value="20241030"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Recommended dose is 0.14 mg/kg/min infused over six minutes as a continuous peripheral intravenous infusion (total dose of 0.84 mg/kg) (<linkHtml href="#LINK_dc7715a2-9618-4979-87c8-a63634ef600e">2</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <observationMedia ID="L53d3399a-3332-4f0d-8223-e67e423cef41">
                     <text>General Formula</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="adrenosine-formula.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_823062f5-800e-40c3-b376-97e4ed5b24e1">
               <id root="a60bf2dd-26b6-45db-8934-c81633c0a0e9"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Injection: 60 mg per 20 mL (3 mg per mL) and 90 mg per 30 mL (3 mg per mL) in single-dose vials containing a sterile, nonpyrogenic, clear, colorless solution of adenosine, USP.</paragraph>
               </text>
               <effectiveTime value="20241030"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Injection: 60 mg per 20 mL (3 mg per mL) and 90 mg per 30 mL (3 mg per mL) in single-dose vialsÂ (<linkHtml href="#LINK_823062f5-800e-40c3-b376-97e4ed5b24e1">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_63ddb3df-5e6e-414c-bebf-23a511dc3872">
               <id root="1d53696d-e781-4f76-8f15-624a9b8d93d6"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Adenosine is contraindicated in patients with: </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Second- or third-degree AV block (except in patients with a functioning artificial pacemaker) <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_0f2cdf77-a7a2-40c7-a538-d3696e0e6c63">5.2</linkHtml>)]</content>
                     </item>
                     <item>Sinus node disease, such as sick sinus syndrome or symptomatic bradycardia (except in patients with a functioning artificial pacemaker) <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_0f2cdf77-a7a2-40c7-a538-d3696e0e6c63">5.2</linkHtml>)]</content>
                     </item>
                     <item>Known or suspected bronchoconstrictive or bronchospastic lung disease (e.g., asthma) <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_e2c51fd2-5276-4f77-8436-e9dcbc991043">5.3</linkHtml>)]</content>
                     </item>
                     <item>Known hypersensitivity to adenosine <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_42d756cd-9142-4f7f-b7e9-ef0baa8de7db">5.7</linkHtml>)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20241030"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>Second- or third-degree AV block (except in patients with a functioning artificial pacemaker) (<linkHtml href="#LINK_63ddb3df-5e6e-414c-bebf-23a511dc3872">4</linkHtml>)</item>
                           <item>Sinus node disease, such as sick sinus syndrome or symptomatic bradycardia (except in patients with a functioning artificial pacemaker) (<linkHtml href="#LINK_63ddb3df-5e6e-414c-bebf-23a511dc3872">4</linkHtml>)</item>
                           <item>Known or suspected bronchoconstrictive or bronchospastic lung disease (e.g., asthma) (<linkHtml href="#LINK_63ddb3df-5e6e-414c-bebf-23a511dc3872">4</linkHtml>)</item>
                           <item>Known hypersensitivity to adenosine (<linkHtml href="#LINK_63ddb3df-5e6e-414c-bebf-23a511dc3872">4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_88f64c9e-8006-465e-a2f5-c2b0175a5e90">
               <id root="0357ba5c-554a-4e02-a83c-b42896613c8f"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <text/>
               <effectiveTime value="20241030"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>
                              <content styleCode="underline">Cardiac Arrest, Ventricular Arrhythmias, and Myocardial Infarction</content>. Fatal cardiac events have occurred. Avoid use in patients with symptoms or signs of acute myocardial ischemia. Appropriate resuscitative measures should be available (<linkHtml href="#LINK_4b43e51e-0f26-4a0c-81b3-558e282c1963">5.1</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Sinoatrial (SA) and Atrioventricular (AV) Nodal Block</content>. First-, second- or third-degree AV block, or sinus bradycardia can occur. Discontinue adenosine if patient develops persistent or symptomatic high-grade AV block (<linkHtml href="#LINK_0f2cdf77-a7a2-40c7-a538-d3696e0e6c63">5.2</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Bronchoconstriction</content>. Can induce dyspnea, bronchoconstriction, and respiratory compromise, especially in patients with obstructive pulmonary disease. Discontinue adenosine if patient develops severe respiratory difficulties (<linkHtml href="#LINK_e2c51fd2-5276-4f77-8436-e9dcbc991043">5.3</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Hypotension</content>. Significant hypotension can occur. Discontinue adenosine if patient develops persistent or symptomatic hypotension (<linkHtml href="#LINK_a6d600ac-359c-43ba-bf67-bbc68cd387bb">5.4</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Cerebrovascular Accidents</content>. Hemorrhagic and ischemic cerebrovascular accidents have occurred (<linkHtml href="#LINK_256d953d-df96-4489-9fe4-77db017d97e5">5.5</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Seizures</content>. New onset or recurrence of convulsive seizures have occurred. Use of methylxanthines (e.g., caffeine, aminophylline and theophylline) is not recommended in patients who experience a seizure in association with adenosine (<linkHtml href="#LINK_d3f4bd20-139c-4e15-82c9-6e54f5aeb4b4">5.6</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Hypersensitivity</content>. Dyspnea, throat tightness, flushing, erythema, rash, and chest discomfort have occurred. Have personnel and resuscitative equipment immediately available (<linkHtml href="#LINK_42d756cd-9142-4f7f-b7e9-ef0baa8de7db">5.7</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Atrial Fibrillation</content>. Reported in patients with or without a history of atrial fibrillation (<linkHtml href="#LINK_1a4e2149-16a5-4559-bab8-5ca37012dd85">5.8</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Hypertension</content>. Clinically significant increases in systolic and diastolic pressure have been observed (<linkHtml href="#LINK_9e294a0a-70ff-45d1-a7f4-4f390c8f7215">5.9</linkHtml>)<br/>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_4b43e51e-0f26-4a0c-81b3-558e282c1963">
                     <id root="6477785b-e67b-4885-a9c0-a634c9bc80da"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Cardiac Arrest, Ventricular Arrhythmias, and Myocardial Infarction</title>
                     <text>
                        <paragraph>Fatal and nonfatal cardiac arrest, sustained ventricular tachycardia (requiring resuscitation), and myocardial infarction have occurred following adenosine infusion. Avoid use in patients with symptoms or signs of acute myocardial ischemia, for example, unstable angina or cardiovascular instability; these patients may be at greater risk of serious cardiovascular reactions to adenosine. Appropriate resuscitative measures should be available <content styleCode="italics">[see Overdosage (<linkHtml href="#LINK_4ccc22cb-405a-46eb-bb4f-9f83d8e8689a">10</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241030"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_0f2cdf77-a7a2-40c7-a538-d3696e0e6c63">
                     <id root="1fcdb3d5-ff38-4f2d-a75a-71aa4f459331"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Sinoatrial and Atrioventricular Nodal Block</title>
                     <text>
                        <paragraph>Adenosine exerts a direct depressant effect on the SA and AV nodes and may cause first-, second- or third-degree AV block, or sinus bradycardia. In clinical trials, approximately 6% of patients developed AV block following adenosine administration (first-degree heart block developed in 3%, second-degree in 3%, and third-degree in 0.8% of patients) <content styleCode="italics">[see Clinical Trials Experience (<linkHtml href="#LINK_6ee006cb-d6f3-4a43-92ce-d729cb56a843">6.1</linkHtml>)]</content>. <br/>
                           <br/>Use adenosine with caution in patients with pre-existing first-degree AV block or bundle branch block. Do not use in patients with high-grade AV block or sinus node dysfunction (except in patients with a functioning artificial pacemaker). Discontinue adenosine in any patient who develops persistent or symptomatic high-grade AV block.</paragraph>
                     </text>
                     <effectiveTime value="20241030"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_e2c51fd2-5276-4f77-8436-e9dcbc991043">
                     <id root="b1acfea4-8ecc-49f7-b71e-1c956adf1c92"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Bronchoconstriction</title>
                     <text>
                        <paragraph>Adenosine administration can cause dyspnea, bronchoconstriction, and respiratory compromise. Adenosine should be used with caution in patients with obstructive lung disease not associated with bronchoconstriction (e.g., emphysema, bronchitis). Do not use in patients with bronchoconstriction or bronchospasm (e.g., asthma). Discontinue adenosine in any patient who develops severe respiratory difficulties. Resuscitative measures should be available prior to adenosine administration <content styleCode="italics">[see Clinical Trials Experience (<linkHtml href="#LINK_6ee006cb-d6f3-4a43-92ce-d729cb56a843">6.1</linkHtml>), Overdosage (<linkHtml href="#LINK_4ccc22cb-405a-46eb-bb4f-9f83d8e8689a">10</linkHtml>), and Clinical Pharmacology (<linkHtml href="#LINK_1555d904-f80b-4012-ac8b-3b638d760efc">12.2</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241030"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_a6d600ac-359c-43ba-bf67-bbc68cd387bb">
                     <id root="ec8ceba9-3eac-4388-8324-69c800b5213a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Hypotension</title>
                     <text>
                        <paragraph>Adenosine is a potent peripheral vasodilator and can induce significant hypotension. The risk of serious hypotension may be higher in patients with autonomic dysfunction, hypovolemia, stenotic valvular heart disease, pericarditis or pericardial effusions, or stenotic carotid artery disease with cerebrovascular insufficiency. Discontinue adenosine in any patient who develops persistent or symptomatic hypotension.</paragraph>
                     </text>
                     <effectiveTime value="20241030"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_256d953d-df96-4489-9fe4-77db017d97e5">
                     <id root="3e77039c-174c-451a-a128-54618ebd8da2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Cerebrovascular Accident</title>
                     <text>
                        <paragraph>Hemorrhagic and ischemic cerebrovascular accidents have occurred. Hemodynamic effects of adenosine including hypotension or hypertension can be associated with these adverse reactionsÂ <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_a6d600ac-359c-43ba-bf67-bbc68cd387bb">5.4</linkHtml>) and (<linkHtml href="#LINK_9e294a0a-70ff-45d1-a7f4-4f390c8f7215">5.9</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241030"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_d3f4bd20-139c-4e15-82c9-6e54f5aeb4b4">
                     <id root="379d7bbb-a185-42cd-b13a-a4d22ac51863"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Seizures</title>
                     <text>
                        <paragraph>New-onset or recurrence of convulsive seizures has occurred following adenosine. Some seizures are prolonged and require emergent anticonvulsive management. Aminophylline may increase the risk of seizures associated with adenosine. Methylxanthine use is not recommended in patients who experience seizures in association with adenosine administration <content styleCode="italics">[see Overdosage (<linkHtml href="#LINK_4ccc22cb-405a-46eb-bb4f-9f83d8e8689a">10</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241030"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_42d756cd-9142-4f7f-b7e9-ef0baa8de7db">
                     <id root="bea6caff-7f58-4623-82f4-36e60f01873f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Hypersensitivity</title>
                     <text>
                        <paragraph>Dyspnea, throat tightness, flushing, erythema, rash, and chest discomfort have occurred. Symptomatic treatment may be required. Have personnel and appropriate treatment available. Resuscitative measures may be necessary if symptoms progress <content styleCode="italics">[see Post-Marketing Experience (<linkHtml href="#LINK_34b4b4b2-4703-4392-9e5e-03d9514af0ea">6.2</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241030"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_1a4e2149-16a5-4559-bab8-5ca37012dd85">
                     <id root="1e96eb8b-2bf8-4923-87eb-76026cfb61eb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Atrial Fibrillation</title>
                     <text>
                        <paragraph>Adenosine can cause atrial fibrillation in patients with or without a history of atrial fibrillation. Atrial fibrillation typically began 1.5 to 3 minutes after initiation of adenosine, lasted for 15 seconds to 6 hours, and spontaneously converted to normal sinus rhythm <content styleCode="italics">[see Post-Marketing Experience (<linkHtml href="#LINK_34b4b4b2-4703-4392-9e5e-03d9514af0ea">6.2</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241030"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_9e294a0a-70ff-45d1-a7f4-4f390c8f7215">
                     <id root="87b9afc2-26d1-4bf3-8f40-a5ded29ca23f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9 Hypertension</title>
                     <text>
                        <paragraph>Adenosine can induce clinically significant increases in systolic and diastolic blood pressure. Most increases resolved spontaneously within several minutes, but in some cases, hypertension lasted for several hours <content styleCode="italics">[see Clinical Trials Experience (<linkHtml href="#LINK_6ee006cb-d6f3-4a43-92ce-d729cb56a843">6.1</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241030"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_51151336-097a-45c8-87e8-a055f3198e9d">
               <id root="5e1d5865-912a-4acb-8eb1-34cf5c74bf20"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following adverse reactions are discussed in more detail in other sections of the prescribing information:</paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>Fatal Cardiac Arrest, Ventricular Arrhythmias, and Myocardial Infarction <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_4b43e51e-0f26-4a0c-81b3-558e282c1963">5.1</linkHtml>)]</content>
                     </item>
                     <item>Sinoatrial and Atrioventricular Nodal Block <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_0f2cdf77-a7a2-40c7-a538-d3696e0e6c63">5.2</linkHtml>)]</content>
                     </item>
                     <item>Bronchoconstriction <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_e2c51fd2-5276-4f77-8436-e9dcbc991043">5.3</linkHtml>)]</content>
                     </item>
                     <item>Hypotension <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_a6d600ac-359c-43ba-bf67-bbc68cd387bb">5.4</linkHtml>)]</content>
                     </item>
                     <item>Cerebrovascular Accident <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_256d953d-df96-4489-9fe4-77db017d97e5">5.5</linkHtml>)]</content>
                     </item>
                     <item>Seizures <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_d3f4bd20-139c-4e15-82c9-6e54f5aeb4b4">5.6</linkHtml>)]</content>
                     </item>
                     <item>Hypersensitivity <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_42d756cd-9142-4f7f-b7e9-ef0baa8de7db">5.7</linkHtml>)]</content>
                     </item>
                     <item>Atrial fibrillation <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_1a4e2149-16a5-4559-bab8-5ca37012dd85">5.8</linkHtml>)]</content>
                     </item>
                     <item>Hypertension <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_9e294a0a-70ff-45d1-a7f4-4f390c8f7215">5.9</linkHtml>)]</content>
                        <br/>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20241030"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (incidence â¥ 10%) are: flushing; chest discomfort; shortness of breath; headache; throat, neck or jaw discomfort; gastrointestinal discomfort; and dizziness (<linkHtml href="#LINK_6ee006cb-d6f3-4a43-92ce-d729cb56a843">6.1</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Meitheal Pharmaceuticals, Inc. at 1-844-824-8426 or FDA at 1-800-FDA-1088 or <content styleCode="underline">www.fda.gov/medwatch</content>.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_6ee006cb-d6f3-4a43-92ce-d729cb56a843">
                     <id root="4cf57d1c-67ef-4ae6-963b-02533953c581"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.<br/>
                           <br/>The following adverse reactions, with an incidence of at least 1%, were reported with adenosine among 1,421 patients in clinical trials. 11% of the adverse reactions occurred several hours after adenosine administration. 8% of the adverse reactions began with adenosine infusion and persisted for up to 24 hours.</paragraph>
                        <paragraph>The most common (incidence â¥ 10%) adverse reactions to adenosine are flushing, chest discomfort, shortness of breath, headache, throat, neck or jaw discomfort, gastrointestinal discomfort, and dizziness (Table 2).</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 2 Adverse Reactions in Clinical Trials (Frequency â¥ 1%)</content>
                        </paragraph>
                        <table>
                           <colgroup>
                              <col width="33%"/>
                              <col width="37%"/>
                           </colgroup>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Adverse Reactions</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Adenosine</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">N=1,421</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Flushing</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                                    <paragraph>44%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Chest discomfort</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                                    <paragraph>40%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Dyspnea</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                                    <paragraph>28%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Headache</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                                    <paragraph>18%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Throat, neck or jaw discomfort</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                                    <paragraph>15%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Gastrointestinal discomfort</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                                    <paragraph>13%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Lightheadedness/dizziness</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                                    <paragraph>12%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Upper extremity discomfort</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                                    <paragraph>4%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>ST segment depression</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                                    <paragraph>3%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>First-degree AV block</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                                    <paragraph>3%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Second-degree AV block</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                                    <paragraph>3%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Paresthesia</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                                    <paragraph>2%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Hypotension</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                                    <paragraph>2%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Nervousness</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                                    <paragraph>2%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <paragraph>Arrhythmias</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                                    <paragraph>1%</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Adverse reactions to adenosine of any severity reported in less than 1% of patients include:</paragraph>
                        <table width="100%" styleCode="Noautorules">
                           <colgroup>
                              <col width="25%"/>
                              <col width="75%"/>
                           </colgroup>
                           <tbody>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Body as a Whole:</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>back discomfort, lower extremity discomfort, weakness</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Cardiovascular System:</paragraph>
                                    <paragraph/>
                                 </td>
                                 <td valign="top">
                                    <paragraph>myocardial infarction, ventricular arrhythmia, third-degree AV block, bradycardia, palpitation, sinus exit block, sinus pause, T-wave changes, hypertension (systolic blood pressure &gt; 200 mm Hg)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Respiratory System:</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>cough</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Central Nervous System:</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>drowsiness, emotional instability, tremors</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Genital/Urinary System:</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>vaginal pressure, urgency</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Special Senses:</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>blurred vision, dry mouth, ear discomfort, metallic taste, nasal congestion, scotomas, tongue discomfort</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20241030"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_34b4b4b2-4703-4392-9e5e-03d9514af0ea">
                     <id root="6dfd25f2-1fa7-4589-abd9-70ab0c926d80"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Post-Marketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been reported from marketing experience with adenosine. Because these reactions are reported voluntarily from a population of uncertain size, are associated with concomitant diseases and multiple drug therapies and surgical procedures, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.<br/>
                        </paragraph>
                        <table width="100%" styleCode="Noautorules">
                           <colgroup>
                              <col width="48%"/>
                              <col width="52%"/>
                           </colgroup>
                           <tbody>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Cardiac Disorders:</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>cardiac arrest, atrial fibrillation, cardiac failure, myocardial infarction, tachycardia, ventricular arrhythmia</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Gastrointestinal Disorders:</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>nausea and vomiting</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>General Disorders and Administration Site Conditions:</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>chest pain, injection site reaction, infusion site pain</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Immune System Disorders:</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>hypersensitivity</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Nervous System Disorders:<br/>
                                    </paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>cerebrovascular accident including intracranial hemorrhage, seizure activity including tonic-clonic (grand mal) seizures, loss of consciousness</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Respiratory, Thoracic and Mediastinal Disorders:</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>bronchospasm, respiratory arrest, throat tightness</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20241030"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_87173a61-b6b4-4f08-bfa6-69be6ec2b9d8">
               <id root="17783504-4319-4255-8f59-833f431e6f1e"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text/>
               <effectiveTime value="20241030"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>Methylxanthines interfere with the activity of adenosine  (<linkHtml href="#LINK_45ca9941-672d-4f0d-a2ff-89b37312c694">7.1</linkHtml>, <linkHtml href="#LINK_4ccc22cb-405a-46eb-bb4f-9f83d8e8689a">10)</linkHtml>
                           </item>
                           <item>Nucleoside transport inhibitors such as dipyridamole can increase the activity of adenosine (<linkHtml href="#LINK_45ca9941-672d-4f0d-a2ff-89b37312c694">7.1</linkHtml>)<br/>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_45ca9941-672d-4f0d-a2ff-89b37312c694">
                     <id root="58a9c167-fb93-4ff0-90f1-a8cac49958df"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Effects of Other Drugs on Adenosine</title>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>The vasoactive effects of adenosine are inhibited by adenosine receptor antagonists, (such as methylxanthines (e.g., caffeine, aminophylline, and theophylline). The safety and efficacy of adenosine in the presence of these agents has not been systematically evaluated <content styleCode="italics">[see Overdosage (<linkHtml href="#LINK_4ccc22cb-405a-46eb-bb4f-9f83d8e8689a">10)</linkHtml>]</content>.</item>
                           <item>The vasoactive effects of adenosine are potentiated by nucleoside transport inhibitors such as dipyridamole. The safety and efficacy of adenosine in the presence of dipyridamole has not been systematically evaluated.</item>
                           <item>Whenever possible, drugs that might inhibit or augment the effects of adenosine should be withheld for at least five half-lives prior to the use of adenosine.</item>
                        </list>
                     </text>
                     <effectiveTime value="20241030"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_cfc8a9fd-dcd5-4753-b3d1-9644607cbc4c">
                     <id root="c9a4a4d2-7fc4-4128-8828-176dc8678219"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Effects of Adenosine on Other Drugs</title>
                     <text>
                        <paragraph>Adenosine injection has been given with other cardioactive drugs (such as beta adrenergic blocking agents, cardiac glycosides, and calcium channel blockers) without apparent adverse interactions, but its effectiveness with these agents has not been systematically evaluated. Because of the potential for additive or synergistic depressant effects on the SA and AV nodes, however, adenosine should be used with caution in the presence of these agents <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_0f2cdf77-a7a2-40c7-a538-d3696e0e6c63">5.2</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241030"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_24f1ab63-aee2-4ce5-876b-81fa9e4f7f01">
               <id root="50da4987-2741-4799-91c4-a653862b9d20"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20241030"/>
               <component>
                  <section ID="LINK_7a221efb-b58d-4fe1-bdb8-46f998690335">
                     <id root="e8373dac-d962-4da3-9048-8a5be48236cc"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20241030"/>
                     <component>
                        <section ID="LINK_16584b4e-dc10-43d7-81b7-55fd8bc3e02d">
                           <id root="af8d2447-c9bf-4bf1-9d06-1a7e486e9b1b"/>
                           <code code="34077-8" codeSystem="2.16.840.1.113883.6.1" displayName="TERATOGENIC EFFECTS SECTION"/>
                           <title>
                              <content styleCode="underline">Teratogenic Effects</content>
                           </title>
                           <text>
                              <paragraph>Animal reproduction studies have not been conducted with adenosine; nor have studies been performed in pregnant women. Because it is not known whether adenosine can cause fetal harm when administered to pregnant women, adenosine should be used during pregnancy only if clearly needed.</paragraph>
                           </text>
                           <effectiveTime value="20241030"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="LINK_715192be-9273-43f8-a663-6d04d2a7ae36">
                     <id root="ba20a258-b58e-4d46-84c5-8a78ae80e20c"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>8.3 Nursing Mothers</title>
                     <text>
                        <paragraph>It is not known whether adenosine is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions from adenosine in nursing infants, the decision to interrupt nursing after administration of adenosine or not to administer adenosine, should take into account the importance of the drug to the mother.</paragraph>
                     </text>
                     <effectiveTime value="20241030"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_ebbf624c-db98-40a4-93bc-fac93249c5fb">
                     <id root="ad094a8b-f7fe-41e6-8f5e-2004d7918432"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of adenosine in patients less than 18 years of age have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20241030"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_cf3e2e81-5ac6-4423-94fc-9fa9e7ad440b">
                     <id root="865da259-6607-42c2-b484-ca650fc35686"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies with adenosine did not include sufficient numbers of subjects aged younger than 65 years to determine whether they respond differently. Other reported experience has not revealed clinically relevant differences of the response of elderly in comparison to younger patients.</paragraph>
                     </text>
                     <effectiveTime value="20241030"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_4ccc22cb-405a-46eb-bb4f-9f83d8e8689a">
               <id root="9d101941-70be-4cb5-80a5-258d77b6d936"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>The half-life of adenosine is less than 10 seconds and adverse reactions of adenosine usually resolve quickly when the infusion is discontinued, although delayed or persistent reactions have been observed. Methylxanthines, such as caffeine, aminophylline, and theophylline, are competitive adenosine receptor antagonists and theophylline has been used to terminate persistent adverse reactions. In clinical trials, theophylline (50 to 125 mg slow intravenous injection) was used to attenuate adenosine adverse reactions in approximately 2% of patients. Methylxanthine use is not recommended in patients who experience seizures in association with adenosine <content styleCode="italics">[see Drug Interactions (<linkHtml href="#LINK_45ca9941-672d-4f0d-a2ff-89b37312c694">7.1</linkHtml>)]</content>.</paragraph>
               </text>
               <effectiveTime value="20241030"/>
            </section>
         </component>
         <component>
            <section ID="LINK_d38ef032-d990-4dc1-8de9-181466c30147">
               <id root="5933d926-900b-441d-9156-d233e983e3f4"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Adenosine, USP is an endogenous nucleoside and is chemically described as 6-Amino-9-<content styleCode="italics">Î²</content>-D-ribofuranosyl-<content styleCode="italics">9H</content>-purine. Adenosine, USP has the following structural formula:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L0411845a-d1b8-431c-97db-b969ac2f9b05"/>
                  </paragraph>
                  <paragraph>
                     <content>The molecular formula for adenosine, USP is C</content>
                     <sub>10</sub>
                     <content>H</content>
                     <sub>13</sub>
                     <content>N</content>
                     <sub>5</sub>
                     <content>O</content>
                     <sub>4</sub>
                     <content> and its molecular weight is 267.24.</content>
                  </paragraph>
                  <paragraph>Adenosine, USP is a white crystalline powder. It is soluble in water and practically insoluble in alcohol. Solubility increases by warming and lowering the pH of the solution.</paragraph>
                  <paragraph>Adenosine injection, USP is a sterile, non-pyrogenic, clear, colorless solution for intravenous use. Each mL of adenosine injection, USP contains adenosine USP, 3 mg and sodium chloride 9 mg in water for injection q.s. The pH of the solution is between 4.5 and 7.5.</paragraph>
               </text>
               <effectiveTime value="20241030"/>
               <component>
                  <observationMedia ID="L0411845a-d1b8-431c-97db-b969ac2f9b05">
                     <text>Structural Formula</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="adenosine-structure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_08f22df4-b4ee-40b5-b859-87ef6e18e583">
               <id root="2696f6a0-1210-4b31-886e-8ebce71b4aca"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20241030"/>
               <component>
                  <section ID="LINK_9843f7b7-a658-4757-8598-9feefc60d969">
                     <id root="44aebb44-ff7b-4480-a6d9-58ac31b682ef"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Adenosine causes cardiac vasodilation which increases cardiac blood flow. Adenosine is thought to exert its pharmacological effects through activation of purine receptors (cell-surface A<sub>1</sub> and A<sub>2</sub> adenosine receptors). Although the exact mechanism by which adenosine receptor activation relaxes vascular smooth muscle is not known, there is evidence to support both inhibition of the slow inward calcium current reducing calcium uptake, and activation of adenylate cyclase through A<sub>2</sub> receptors in smooth muscle cells. Adenosine may also lessen vascular tone by modulating sympathetic neurotransmission. The intracellular uptake of adenosine is mediated by a specific transmembrane nucleoside transport system. Once inside the cell, adenosine is rapidly phosphorylated by adenosine kinase to adenosine monophosphate, or deaminated by adenosine deaminase to inosine. These intracellular metabolites of adenosine are not vasoactive. <br/>
                           <br/>Myocardial uptake of thallium-201 is directly proportional to coronary blood flow. Since adenosine significantly increases blood flow in normal coronary arteries with little or no increase in stenotic arteries, adenosine causes relatively less thallium-201 uptake in vascular territories supplied by stenotic coronary arteries i.e., a greater difference is seen after adenosine between areas served by normal and areas served by stenotic vessels than is seen prior to adenosine.</paragraph>
                     </text>
                     <effectiveTime value="20241030"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_1555d904-f80b-4012-ac8b-3b638d760efc">
                     <id root="8ddab712-97c0-4a45-851c-51d07fa97fff"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Hemodynamic Effects </content>
                           <br/>
                           <br/>Adenosine produces a direct negative chronotropic, dromotropic and inotropic effect on the heart, presumably due to A<sub>1</sub>-receptor agonism, and produces peripheral vasodilation, presumably due to A<sub>2</sub>-receptor agonism. The net effect of adenosine in humans is typically a mild to moderate reduction in systolic, diastolic and mean arterial blood pressure associated with a reflex increase in heart rate. Rarely, significant hypotension and tachycardia have been observed <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_a6d600ac-359c-43ba-bf67-bbc68cd387bb">5.4</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241030"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_88ae671b-e100-4147-aa9f-4954441a5663">
                     <id root="20c4ef12-7f17-4e25-ae31-1e56dc1220a8"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                           <br/>
                           <br/>Intravenously administered adenosine distributes from the circulation via cellular uptake, primarily by erythrocytes and vascular endothelial cells. This process involves a specific transmembrane nucleoside carrier system that is reversible, nonconcentrative, and bidirectionally symmetrical. <br/>
                           <br/>
                           <content styleCode="underline">Metabolism</content>
                           <br/>
                           <br/>Intracellular adenosine is metabolized either via phosphorylation to adenosine monophosphate by adenosine kinase, or via deamination to inosine by adenosine deaminase in the cytosol. Since adenosine kinase has a lower K<sub>m</sub> and V<sub>max</sub> than adenosine deaminase, deamination plays a significant role only when cytosolic adenosine saturates the phosphorylation pathway. Inosine formed by deamination of adenosine can leave the cell intact or can be degraded to hypoxanthine, xanthine, and ultimately uric acid. Adenosine monophosphate formed by phosphorylation of adenosine is incorporated into the high-energy phosphate pool. <br/>
                           <br/>
                           <content styleCode="underline">Elimination</content>
                           <br/>
                           <br/>While extracellular adenosine is primarily cleared from plasma by cellular uptake with a half-life of less than 10 seconds in whole blood, excessive amounts may be deaminated by an ecto-form of adenosine deaminase. <br/>
                           <br/>
                           <content styleCode="underline">Specific Populations </content>
                           <br/>
                           <br/>
                           <content styleCode="italics">Renal Impairment</content>
                           <br/>As adenosine does not require renal function for its activation or inactivation, renal impairment would not be expected to alter its effectiveness or tolerability.<br/>
                           <br/>
                           <content styleCode="italics">Hepatic Impairment</content>
                           <br/>As adenosine does not require hepatic function for its activation or inactivation, hepatic impairment would not be expected to alter its effectiveness or tolerability.</paragraph>
                     </text>
                     <effectiveTime value="20241030"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_39f985d2-3d7a-4ead-8bc1-35e2d60f8b51">
               <id root="747e4356-7893-44b8-b793-a07c095796a5"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20241030"/>
               <component>
                  <section ID="LINK_bda049a6-ba45-4772-ad9c-24423bb5c566">
                     <id root="ea1712ac-0598-47c0-9ec4-9f8b4501a1a1"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Studies in animals have not been performed to evaluate adenosineâs carcinogenic potential or potential effects on fertility. Adenosine was negative for genotoxic potential in the Salmonella (Ames Test) and Mammalian Microsome Assay.</paragraph>
                        <paragraph>Adenosine, however, like other nucleosides at millimolar concentrations present for several doubling times of cells in culture, is known to produce a variety of chromosomal alterations.</paragraph>
                     </text>
                     <effectiveTime value="20241030"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_5b02fc5c-116e-44a7-abc0-0ec2932e2f66">
               <id root="5606ba5a-329c-4514-86eb-a139fe93dd4b"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>In two crossover comparative studies involving 319 subjects who could exercise (including 106 healthy volunteers and 213 patients with known or suspected coronary disease), adenosine and exercise thallium images were compared by blinded observers. The images were concordant for the presence of perfusion defects in 85.5% of cases by global analysis (patient by patient) and up to 93% of cases based on vascular territories.</paragraph>
                  <paragraph>In the two studies, 193 patients also had recent coronary arteriography for comparison (healthy volunteers were not catheterized). The sensitivity for detecting angiographically significant disease (â¥ 50% reduction in the luminal diameter of at least one major vessel) was 64% for adenosine and 64% for exercise testing. The specificity was 54% for adenosine and 65% for exercise testing. The 95% confidence limits for adenosine sensitivity were 56% to 78% and for specificity were 37% to 71%.</paragraph>
                  <paragraph>Intracoronary Doppler flow catheter studies have demonstrated that a dose of intravenous adenosine of 0.14 mg/kg/min produces maximum coronary hyperemia (relative to intracoronary papaverine) in approximately 95% of cases within two to three minutes of the onset of the infusion. Coronary blood flow velocity returns to basal levels within one to two minutes of discontinuing the adenosine infusion.</paragraph>
               </text>
               <effectiveTime value="20241030"/>
            </section>
         </component>
         <component>
            <section ID="LINK_801e0226-b07f-41c7-83e8-8a69fc6d8efd">
               <id root="f8a151e1-9408-479c-acb0-9ac1061110d9"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <effectiveTime value="20241030"/>
               <component>
                  <section ID="LINK_6b290856-1eeb-49c1-ae8b-627fcc0b6984">
                     <id root="f1cbbe47-eb64-4a98-91bc-d7d0a5535f78"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>How Supplied</title>
                     <text>
                        <paragraph>Adenosine injection, USP is supplied as 60 mg per 20 mL (3 mg per mL) and 90 mg per 30 mL (3 mg per mL) in single-dose vials of clear, colorless solution in normal saline.</paragraph>
                        <table width="100%" styleCode="Noautorules">
                           <caption/>
                           <tbody>
                              <tr>
                                 <td>
                                    <content styleCode="bold">NDC</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Adenosine Injection, USP (3 mg per mL)</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Â Package Factor</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>71288-<content styleCode="bold">207</content>-21</td>
                                 <td>60 mg per 20 mL Single-Dose Vial</td>
                                 <td>Â 10 vials per carton</td>
                              </tr>
                              <tr>
                                 <td>71288-<content styleCode="bold">208</content>-30</td>
                                 <td>90 mg per 30 mL Single-Dose Vial</td>
                                 <td>Â 1 vial per carton</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20241030"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_f1ad928a-43e7-438c-920c-254a48671d6f">
                     <id root="cddd72e1-d321-4ab8-892d-b9b25ea0f3fa"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <title>Storage and Handling</title>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>Store at 20Â° to 25Â°C (68Â° to 77Â°F) [see USP Controlled Room Temperature].</item>
                           <item>Do not refrigerate as crystallization may occur. If crystallization has occurred, dissolve crystals by warming to room temperature. The solution must be clear at the time of use</item>
                           <item>Discard unused portion</item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">Sterile, Nonpyrogenic, Preservative-free.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">The container closure is not made with natural rubber latex.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241030"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_50e4bc06-23e9-441c-800e-5a84a48694ed">
               <id root="4e29c227-a1c1-4375-81b6-9d803299f371"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <list listType="unordered" styleCode="Disk">
                     <item>Advise patients that they may be at increased risk of fatal and nonfatal heart attacks, abnormal heart rhythms, cardiac arrest, heart block, significant increase or decrease in blood pressure, bronchoconstriction, hypersensitivity reactions, seizures, or cerebrovascular accidents with the use of adenosine <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_4b43e51e-0f26-4a0c-81b3-558e282c1963">5.1</linkHtml> to <linkHtml href="#LINK_9e294a0a-70ff-45d1-a7f4-4f390c8f7215">5.9</linkHtml>)]</content>.</item>
                     <item>Advise patients with COPD or asthma to discuss their respiratory history with their clinician before scheduling a myocardial perfusion imaging study with adenosine <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_e2c51fd2-5276-4f77-8436-e9dcbc991043">5.3</linkHtml>)]</content>.</item>
                     <item>Methylxanthines have the potential to impact the effects of adenosine. Instruct patients to avoid consumption of any products containing methylxanthines, including caffeinated coffee, tea or other caffeinated beverages, caffeine- containing drug products, aminophylline, and theophylline prior to the myocardial perfusion imaging study. Question patients about a history of seizures <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_d3f4bd20-139c-4e15-82c9-6e54f5aeb4b4">5.6</linkHtml>), Drug Interactions (<linkHtml href="#LINK_45ca9941-672d-4f0d-a2ff-89b37312c694">7.1</linkHtml>), and Overdosage (<linkHtml href="#LINK_4ccc22cb-405a-46eb-bb4f-9f83d8e8689a">10</linkHtml>)]</content>.</item>
                  </list>
                  <paragraph>meitheal<sub>Â®</sub>
                  </paragraph>
                  <paragraph>Mfd. for Meitheal Pharmaceuticals<br/>Chicago, IL 60631 (USA)<br/>Â©2024 Meitheal Pharmaceuticals Inc.</paragraph>
                  <paragraph>Mfd. by Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.<br/>Nanjing, China 210061</paragraph>
                  <paragraph>October 2024</paragraph>
                  <paragraph>8S8ACM9-00</paragraph>
               </text>
               <effectiveTime value="20241030"/>
            </section>
         </component>
         <component>
            <section ID="LINK_71885bc9-c95a-4edb-99e6-9a4369670a74">
               <id root="b5a1005b-31a9-4f54-bb28-9fb27eea3a44"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL -Â Adenosine Injection, USP 60 mg per 20 mL Container Label</title>
               <text>
                  <paragraph>NDC 71288-<content styleCode="bold">207</content>-20</paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">AdenosineÂ </content>
                     <content styleCode="bold">Injection, USP</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">60 mg per 20 mL</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(3 mg per mL)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">FOR INTRAVENOUS INFUSIONÂ </content>
                     <content styleCode="bold">ONLY</content>
                  </paragraph>
                  <paragraph>Sterile, Nonpyrogenic</paragraph>
                  <paragraph>
                     <content styleCode="bold">Discard Unused Portion</content>
                  </paragraph>
                  <paragraph>20 mL Single-Dose Vial</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L799a61eb-7040-482f-af21-2433c4e12eef"/>
                  </paragraph>
               </text>
               <effectiveTime value="20241030"/>
               <component>
                  <observationMedia ID="L799a61eb-7040-482f-af21-2433c4e12eef">
                     <text>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 60 mg per 20 mL Container Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="adenosine-60mg-vial.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_257f0c61-822d-4ae7-9cdc-299787f8bce7">
               <id root="c411b182-b75e-48f6-a6e1-aece853b6f1b"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL -Â Adenosine Injection, USP 60 mg per 20 mL Carton</title>
               <text>
                  <paragraph>NDC 71288-<content styleCode="bold">207</content>-21</paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Adenosine Injection, USP</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">60 mg per 20 mL</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(3 mg per mL)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">FOR INTRAVENOUS INFUSION ONLY</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Discard Unused Portion</content>
                  </paragraph>
                  <paragraph>10 x 20 mL Single-Dose Vials</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L948af2dd-251b-4892-9b53-af938ec5309e"/>
                  </paragraph>
               </text>
               <effectiveTime value="20241030"/>
               <component>
                  <observationMedia ID="L948af2dd-251b-4892-9b53-af938ec5309e">
                     <text>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 60 mg per 20 mL Carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="adenosine-60mg-carton.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="L2e970793-2fc5-44f8-8566-66e5d3d5caea">
               <id root="bd5d8d47-b6c2-4cf3-b278-2b0827c859ac"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - Adenosine Injection, USP 90 mg per 30 mL Container Label</title>
               <text>
                  <paragraph>NDC 71288-<content styleCode="bold">208</content>-30</paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Adenosine Injection, USP</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">90 mg per 30 mL</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(3 mg per mL)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">FOR INTRAVENOUS INFUSION ONLY</content>
                  </paragraph>
                  <paragraph>Sterile, Nonpyrogenic</paragraph>
                  <paragraph>
                     <content styleCode="bold">Discard Unused Portion</content>
                  </paragraph>
                  <paragraph>30 mL Single-Dose Vial</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L4d0007ae-f218-46db-b4e4-fd33e5a4f58d"/>
                  </paragraph>
               </text>
               <effectiveTime value="20241030"/>
               <component>
                  <observationMedia ID="L4d0007ae-f218-46db-b4e4-fd33e5a4f58d">
                     <text>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 90 mg per 30 mL Container Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="adenosine-90mg-vial.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Lab579fb1-71ab-4d38-97d5-872b604d9167">
               <id root="fa927cda-3df3-4ddf-8e56-c7083987d8f2"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - Adenosine Injection, USP 90 mg per 30 mL Carton</title>
               <text>
                  <paragraph>NDC 71288-<content styleCode="bold">208</content>-30</paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Adenosine Injection, USP</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">90 mg per 30 mL</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(3 mg per mL)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">FOR INTRAVENOUS INFUSION ONLY</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Discard Unused Portion</content>
                  </paragraph>
                  <paragraph>1 x 30 mL Single-Dose Vial</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L3d52ca2d-87e2-4fcc-90a1-de251a8c9ee4"/>
                  </paragraph>
               </text>
               <effectiveTime value="20241030"/>
               <component>
                  <observationMedia ID="L3d52ca2d-87e2-4fcc-90a1-de251a8c9ee4">
                     <text>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 90 mg per 30 mL Carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="adenosine-90mg-carton.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>